retatrutide nash trial Retatrutide: A deep dive Part 1 in a series covering what is and does as well as it's current status with the FDA Phase 2 trial results demonstrate
Description
In addition, studies revealed that SGLT-2is could reduce the risk of chronic heart failure in people with type 2 diabetes

L., Reynolds L
But the cardiovascular indication for Wegovy (approved March 2024) and the MASH indication (approved August 2025) create additional coverage pathways even without the Bridge

Potential Risks and Side Effects Improper mixing of Semaglutide with Bacteriostatic Water can lead to critical health complications

Early court documents show that this case will be about whether the manufacturer properly warned of the side effects
